PROTOTYPE DRUG Cyclophosphamide Cytoxan

Document Sample
PROTOTYPE DRUG Cyclophosphamide Cytoxan Powered By Docstoc
					                                      Nursing Process Focus:
                         Patients Receiving Cyclophosphamide (Cytoxan)
Assessment                                            Potential Nursing Diagnoses
Prior to administration:                                  Body image, disturbed, risk for,
  Obtain complete health history including                  related topossible alopecia and other
     allergies, drug history and possible drug               side effects of medication which cause
     interactions                                            changes in appearance
  Assess for presence/history of specific type           Fluid volume, deficient, risk for,
     of cancer, bone marrow suppression, tumor               related to nausea, vomiting, diarrhea
     cell infiltraton of bone marrow, recent              Infection, risk for, related to
     chemotherapy or radiation.                              compromised immune system
  Obtain kidney, and liver function tests                Knowledge, deficient, related to no
  Assess platelet count                                     previous experience with medication
  Assess for symptoms of compromised                     Noncompliance, related to
     immune system                                           unacceptance of diagnosis, unpleasant
                                                             side effects of medication
                                                          Nutrition, imbalanced, less than body
                                                             requirements, related to nausea,
                                                             vomiting, diarrhea, anorexia
                                                          Tissue integrity, Risk for impaired,
                                                             related to extravasation of IV
                      Planning: Patient Goals and Expected Outcomes
Patient will:
  Demonstrate absence of serious adverse effects
  Exhibit acceptance of expected side effects
  Demonstrate compliance with recommended therapeutic regimen
  Demonstrate knowledge of mechanism of action of cyclophosphamide
  Demonstrate understanding of which side effects to report immediately
             Interventions and (Rationales)           Patient Education/Discharge Planning
  Evaluate baseline data, including general           Advise patient of importance of complete
     health status, vital signs, weight, lab results,     work-up prior to beginning
     specific type of cancer.                             chemotherapy.
  Monitor for anemia and leukopenia, two             Instruct patient to:
     most common indicators of                         Notice and report fever of unknown
     myelosuppression. (If present, patient will          origin, chills, sore throat, bruising,
     be unable to protect self against even               unusual bleeding
     smallest infection.)                              Avoid others with infections
  Monitor for cardiac problems.                       Instruct patient to report immediately
     (Myopericarditis may occur and is a sign of          tachycardia, dyspnea, fever, or chills.
     a serious adverse reaction to medication.)
  Monitor for respiratory problems. (Patient         Instruct patient to:
     may experience cough and dyspnea;                 Be aware of any new respiratory
     medication can cause fibrosis in lungs,              problems
    which would decrease functional capacity of         Report cough with or without sputum
    lungs.)                                              production, dyspnea, inability to do
                                                         previous activities because of fatigue
   Observe for hematuria. (Hemorrhagic              Instruct patient to:
    cystitis may result from cyclophosphamide         Consume 3000cc fluids/day (3
    use secondary to continuous irritation of            quarts/day) on day before treatment and
    bladder from medication.)                            for 72 hours after, if not contraindicated
                                                         by another condition
                                                      Be aware of color changes in urine and
                                                         report immediately
                                                      Have routine urinalysis performed
                                                      Not take cyclophosphamide at bedtime
                                                         because voiding during night is too
                                                         infrequent to prevent cystitis
                                                      Report any signs of a UTI because
                                                         cystitis can occur up to several months
                                                         after cyclophosphamide use is
   Monitor for side effects/adverse reactions.       Instruct patient to report nausea,
                                                         vomiting, anorexia, diarrhea, abdominal
                                                         pain, headache, swollen lips, rash,
                                                         darkening of skin and nails, missed
   Observe for alopecia. (All chemotherapeutic       Reassure patient that hair growth will
    agents attack normal, fast-growing cells as          reoccur after completion of
    well as cancer cells; hair cells are very fast       cyclophosphamide therapy, but hair may
    growing, so hair growth stops and hair will          be a different color and/or texture
    fall out.)
   Provide emotional support to patient and
   Refer patient to ACS or other legitimate
    support groups and to get a wig before hair
    loss requires it, to ease transition
    Monitor for herpes zoster or chickenpox. (If      Instruct patient that he/she or members of
     patient recently had either herpes zoster or       household should not be vaccinated
     chickenpox, has now, or has been exposed           against chickenpox during therapy.
     to chicken pox, he/she cannot take
     cyclophosphamide; it may cause
     exacerbation or increased severity of herpes
     or chickenpox. Patient is
     immunosuppressed because of medication,
     so his/her body cannot fight against a live
     virus introduced to it.)
    Monitor for decreased hepatic functioning         Instruct patient to be aware of yellowing
     (Cyclophosphamide is metabolized in liver          of skin or whites of eyes, color changes in
     Decreased hepatic functioning could lead to        stool from brown to clay-colored, and to
     toxicity, since liver may not be able to           report immediately.
     metabolize drug, therefore there will be
     increased levels in body.)
    Monitor for decreased kidney                     Instruct patient to note and report any
     functioning.(Cyclophosphamide is excreted         changes in urinary function: decreased
     through kidneys.)                                 urination, changes in color or odor of
                                                       urine, generalized edema.
  Evaluate for overdose. Symptoms include:          Instruct patient to notify health care
    nausea, vomiting, anorexia, alopecia,              provider if symptoms appear, and that
    myelosuppression.                                  treatment will be supportive (control of
                                                       nausea or vomiting, etc.).
  Monitor for diabetes mellitus. (Patient may       Advise patient to monitor blood sugar
    lose glycemic control; symptoms of                 daily and report to health care provider if
    hypoglycemia may appear secondary to               trends become apparent (either hypo- or
    combination of cyclophosphamide and                hyperglycemia). Hypoglycemic
    insulin.)                                          medication doses may need to be adjusted
                                                       during therapy
                                 Evaluation of Outcome Criteria
Evaluate the effectiveness of drug therapy by confirming that patient goals and expected
outcomes have been met (see “Planning”).
                                       Nursing Process Focus:
                   Patients Receiving METHOTREXATE (MTX, Folex PFS)
Assessment                                        Potential nursing diagnoses
Prior to administration:                               Body image, disturbed, related to side
  Obtain complete health history including               effects of medication
      allergies, drug history and all medications      Fluid volume, deficient, risk for related
      for possible drug interactions                      to nausea/vomiting, anorexia, secondary
  Assess kidney, liver function, CBC, and                to methotrexate
      platelet count                                   Knowledge, deficient, related to no
  Assess for presence/history of specific                prior experience with this medication
      type of cancer, decreased hepatic or renal       Protection, ineffective, related to
      function, bone marrow depression, herpes            immunosuppressive effects of
      zoster, chicken pox.                                methotrexate
                                                       Therapeutic regimen management,
                                                          ineffective, related to inability to cope
                                                          with side effects, diagnosis, prognosis
                         Planning: Patient Goals and Expected Outcomes
Patient will report:
     Acceptance of need for therapy with methotrexate
     Ability to cope with expected side effects
     Absence of serious side effects/adverse reactions
     Presence of any of above
Patient and family will express understanding of:
     Mechanisms of action of methotrexate
     Common, expected side effects and methods to decrease severity
           Interventions and (Rationales)           Patient Education/Discharge Planning
  If patient is to receive high dose                Advise patient of the importance of
     methotrexate with leukovorin rescue,               complete physical exam with lab studies
     baseline urine pH must be done. (Patient’s         prior to beginning methotrexate therapy
     pH must be maintained at 7 or > (alkaline          and to have periodic lab studies performed
     urine) in order for methotrexate to be             during therapy with methotrexate
     adequately eliminated through kidneys           Inform patient about ways to keep urine
     and to decrease chance of kidney                   pH at 7 or above: drink cranberry juice
     damage.)                                           daily, increase fluid consumption, avoid
                                                        highly acidic fluids such as orange or
                                                        grapefruit juice
  Monitor immune status. (Methotrexate              Advise patient to avoid persons with URIs
     should not be given if patient is                  and other infectious conditions while
     immunodeficient; medication would                  receiving methotrexate.
     further deplete WBC reserves, and
     increase patient’s risk of developing
     infections which could be life-
  Monitor for GI side effects, including           Teach patient:
    nausea/vomiting, ulcers, GI bleeding,          Steps to decrease side effects, early
    stomatitis. (Chemotherapeutic agents              recognition of problems
    attack fastest growing cells, which include    To request anti-emetic as needed
    cells in GI tract, which are destroyed,        To consume frequent, small meals, dietary
    causing these side effects.)                      supplements if needed, high calorie
   Administer anti-emetic as needed                  liquids as needed
   Observe for alopecia. (Hair loss can be        Inform patient about local support groups
    upsetting to patient, especially female           such as ACS
    patient.)                                      Reassure patient that hair regrowth will
   Refer to support group.                           occur after methotrexate therapy
                                                      completed, but hair may be different color
                                                      or texture.
   Monitor for integumentary side effects        Instruct patient to:
    such as rash, pruritis, acne, boils. (These    Be aware of any rash, pruritis, acne, boils
    may occur secondary to fact that highest       Use unscented lotion on rash or pruritic
    doses of methotrexate are found in skin           areas
    (as well as in kidneys, liver, spleen and      Report any new acne or boil formation
    gallbladder), and may cause severe skin
   Monitor platelet count. (If platelet count    Teach patient to:
    decreased, avoid invasive procedures or        Regularly examine skin, mucous
    use extreme caution; hemorrhage could             membranes, injection sites for bruising or
    occur secondary to patient lacking                bleeding
    adequate platelets for blood                   Use soft toothbrush, electric razor, and to
    coagulation/clotting)                             avoid nail clippers, toothpicks or anything
   Test urine, stool, emesis for occult blood        else that could cause bleeding
   Evaluate fluid intake. (A higher fluid         Advise patient to maintain 3000cc/day (3
    intake will lead to increased urine               quarts/day) fluid intake unless
    production, which will decrease chance of         contraindicated
    kidney damage occurring as result of           Instruct patient concerning items he/she
    methotrexate.)                                    can consume that are not liquid but count
                                                      towards intake, including gelatin, ice
                                                      cream, popsickles, etc.
   Monitor for gout or history of urate          Instruct patient:
    kidney stones. (Patient has increased          Of importance of complete disclosure of
    chance of worsening hyperuricemia,                past medical history
    because kidneys are one of areas in body       To report immediately severe, sudden
    which has highest distribution of                 pain in joints especially great toe or
    methotrexate, as well as where drug is            fingers; severe sudden flank pain;
    excreted, therefore it can be “laid down”         decreased ability to urinate
    there, causing irritation or stone
   Obtain history of herpes zoster or            Advise patient/family to:
    chickenpox, actual or exposure to. (Patient    Avoid exposure to chickenpox or herpes
    has risk of more severe, generalized             zoster
    disease occurring.)                               Avoid vaccinations during time patient
                                                       receiving methotrexate
                                Evaluation of Outcome Criteria
Evaluate the effectiveness of drug therapy by confirming that patient goals and expected
outcomes have been met (see “Planning”).
                                      Nursing Process Focus:
                       Patients Receiving DOXORUBICIN (Adriamycin)
Assessment                                       Potential Nursing Diagnoses
Prior to administration:                              Body image, disturbed, related to
  Obtain complete health history including               physical changes secondary to
     allergies, drug history and possible drug            doxorubicin
     interactions                                     Fluid volume, deficient, risk for,
  Assess for presence/history of                         related to diarrhea, nausea/vomiting
     Specific neoplasia present                          secondary to medication
     Decreased hepatic functioning                   Knowledge, deficient, related to no
     Decreased bone marrow or infiltration               previous contact with cancer or its
        of marrow by tumor cells                          treatments
     Gout or urate kidney stones                     Nutrition, less than body
     Radiation therapy                                   requirements, related to anorexia,
     Cardiac problems                                    nausea/vomiting, diarrhea secondary
     Side effects/adverse reactions                      to medication
     Overdose                                        Oral mucous membranes, impaired,
     Age of patient                                      related to stomatitis secondary to
     Herpes zoster or chickenpox, disease or
        recent exposure                               Skin integrity, impaired, risk for,
                                                          related to extravasation, cellulitis
     Other medications patient is taking
     Pregnancy/lactation
                    Planning: Patient Goals and Expected Outcomes
Patient will:
     Demonstrate symptoms of clinical improvement
     Experience absence of adverse reactions
     Demonstrate understanding of mechanism of action of doxorubicin
     Demonstrate understanding of expected side effects, and measures to decrease their
     Adverse reactions to report
           Interventions and (Rationales)           Patient Education/Discharge Planning
  Obtain baseline information including            Advise patient of importance of
     vital signs, EKG and other cardiac work-          complete physical exam prior to and
     ups, CBC and other blood studies.                 periodically during treatment with
  Monitor for stomatitis or ulcerations.        Advise patient to:
     (They are common side effects of               Examine mouth daily for signs of
     doxorubicin, secondary to destruction of          breakdown of mucous membranes
     fastest growing cells by chemotherapeutic      Use only soft bristle toothbrush, avoid
     agents.) If necessary, a special mouth            hard or spicy foods likely to cause
     rinse may be ordered.                             irritation, avoid toothpicks
   Monitor hepatic functioning.                     Instruct patient to keep appointments for
    (Doxorubicin is metabolized in liver, so          lab work.
    decreased liver function can lead to
    doxorubicin toxicity.)
   Monitor intake and output. (Increased        Advise patient:
    fluids will increase urine production and      To drink 2-3 quarts fluids/day, unless
    increase elimination of uric acid, leading       contraindicated by another condition
    to decreased chance of urate kidney stone      About other substances that can be
    formation.)                                      substituted for part of fluids: gelatin,
                                                     popsickles, ice cream, etc.
   Observe color of urine. (Doxorubicin will      Advise patient to be aware of color
    turn urine red-brown in color for 1-2 days       changes in urine, and that it is not
    after administration.)                           hematuria but is an effect of the
                                                     medication itself.
   Monitor for nausea or vomiting. Patient      Teach patient/family:
    should have prescription for anti-emetic       Proper use of anti-emetic at home
    for use at home if needed.                     To take anti-emetic at first sign of
                                                     nausea, not to wait until vomiting
                                                   Concerning other measures to decrease
                                                     nausea/vomiting (small meals, cold
                                                     rather than room temperature liquids,
                                                     pleasant dining surroundings, remove
                                                     unnecessary items from dining area,
                                                     avoid strong odors, etc.)
   Observe for skin changes. (Doxorubicin       Advise patient:
    may cause soles of feet, palms of hands,       that doxorubicin may cause soles of feet,
    nail beds to darken. Cellulitus may occur        palms of hands, nail beds to darken and
    at IV site secondary to irritation from          to not be alarmed if this happens
    medication; if present, change IV site,        To note and report immediately any
    apply warm cloths, elevate extremity if          redness, heat, swelling at IV site
   Ensure that EKG is obtained (Toxicity        Instruct patient to
    may show up as T-wave flattening, sinus         Have periodic EKG done and if EKG
    tachycardia, ST depression, voltage                changes are present, medication will be
    reduction on EKG secondary to cardiac              discontinued because they are a sign of
    depression. CHF may not appear for up to           drug toxicity
    6 months after completion of doxorubicin        Report signs of CHF (pedal edema, neck
    therapy. Cardiotoxicity is more common             vein distention, fatigue, dyspnea, etc.)
    in patients over age 70 and under age 2,           Signs of CHF may not appear
    because their cardiac systems are more             immediately
    susceptible to certain medications,
    including doxorubicin.)
    Monitor WBC. (WBC usually lowest 10-             Advise patient:
     14 days after dose of doxorubicin, and           That susceptibility to infections is
     returns to patient’s normal within 21             greatest when WBC is decreased
     days.)                                           To avoid persons with URIs, other
                                                       infectious diseases
                                                      To report fever, chills, sore throat, etc.
    Obtain history of radiation therapy,             Advise patient of importance of
     current or in past. (Doxorubicin cannot be        complete disclosure of past medical
     used if patient experienced marked                history and treatments.
     myelosuppression from radiation therapy;
     he/she would suffer further
    Monitor for flu-like symptoms. (May be           Instruct patient about which symptoms
     symptom of impending toxicity.). Report           to report immediately: nausea, vomiting,
     immediately                                       diarrhea, anorexia.
    Monitor for alopecia. (Alopecia                  Advise patient that hair loss is
     commonly occurs with doxorubicin                  temporary, and hair re-growth will occur
     therapy, secondary to fact that                   after completion of doxorubicin therapy,
     chemotherapeutic agents attack fastest            but hair may be different texture or
     growing cells in body (including hair             color.
     cells), and destroy them, causing hair           Advise patient about local support
     loss.)                                            groups such as ACS
    Provide emotional support.                       Encourage patient to get wig and start
                                                       wearing before hair loss is severe
   Monitor for side effects/adverse reactions        Instruct patient/family to report facial
    patient may experience, including facial           swelling, flushing, headache, chills,
    swelling, flushing, headache, chills, back         back pain, tightness in chest and throat,
    pain, tightness in chest and throat,               dizziness, weakness, desquamation of
    hypotension, desquamation of skin on               skin on hands and feet, conjunctivitis.
    hands and feet, conjunctivitis in addition
    to those side effects already listed above.
    Report to health care provider.
  Monitor for symptoms of overdose.                 Instruct patient to report any changes in
    Symptoms include nausea/vomiting,                  how he/she feels immediately and that
    myelosuppression, irreversible cardiac             treatment will depend on which
    toxicity, or mucositis. Report                     symptoms appear, and will most likely
    immediately.                                       be done on in-patient basis
                          Evaluation of Outcome Criteria
Evaluate the effectiveness of drug therapy by confirming that patient goals and expected
outcomes have been met (see “Planning”).
                                     Nursing Process Focus:
                          Patients Receiving VINCRISTINE (Oncovin)
Assessment                                      Potential Nursing Diagnoses
Prior to administration:                             Body image, disturbed, related to
  Obtain complete health history including            alopecia and other side effects
     allergies, drug history and possible drug       Fluid volume, deficient, risk for,
     interactions.                                     related to diarrhea, vomiting secondary
  Assess for presence/history of specific             to side effects of vincristine
     cancer, bone marrow depression,                 Nutrition, imbalanced, less than body
     radiation treatement, herpes zoster or            requirements, related to loss of appetite
     chicken pox, infection                            secondary to vincristine
                                                     Protection, ineffective, related to
                                                       decreased WBC secondary to
                                                     Tissue integrity, impaired, related to
                                                       extravasation at IV site with resultant
                      Planning: Patient Goals and Expected Outcomes
Patient will:
     Experience minimal adverse reactions to vincristine
     Demonstrate knowledge of mechanisms of action of vincristine
     Demonstrate knowledge of measures to decrease severity of side effects and increase
             Interventions and (Rationales)         Patient Teaching/Discharge Planning
     Monitor for decreased hepatic              Instruct patient to:
      functioning. (Vincristine is metabolized    Get regular liver function tests performed
      in liver)                                   Report any signs of decreased liver
                                                      function: yellowing of skin or whites of
                                                      eyes, clay-colored stools
     Monitor for infection. (Bone marrow         Teach patient and caregiver methods to
      suppression may occur, with resultant           decrease exposure to infections: stay away
      immunosuppression.)                             from persons with URIs, decrease
                                                      exposure to children, get adequate sleep,
                                                      try to eat well-balanced diet and to report
                                                      any fever, increased fatigue, sore throat,
                                                      etc. immediately
     Monitor for symptoms of neurologic or       Advise patient and caregiver to monitor
      neuromuscular side effects. (The most           for sensory impairment (decreased
      serious limiting adverse effects of             sensations, vision or hearing), numbness
      vincristine relate to nervous system            or tingling of fingers or toes, ataxia and to
      toxicity.)                                      report immediately
     Monitor kidney function. (Vincristine      Advise patient to:
      may cause SIADH, evident by                 Increase fluid intake to 2-3quarts/day
    concentrated urine and retention of free         Report symptoms of SIADH which
    water.)                                           include: decreased urination, darker color
                                                      or strong odor to urine, weight gain
                                                  Report immedialey lower back pain which
                                                      may be the 1st symptom of uric acid
                                                  Be alert for and report increased or
                                                      decreased urination, bed wetting—these
                                                      may be symptoms of autonomic toxicity
   Monitor baseline labs and periodic lab       Teach patient:
    results during vincristine therapy,           The importance of lab studies prior to and
    including hematocrit, hemoglobin,                periodically during vincristine therapy
    platelets, WBC. (Decreased blood counts  About energy conservation methods, such
    put patient at higher risk for infection or      as frequent rest periods, planning activities
    fatigue.)                                        during times of highest energy levels,
                                                     allowing others to assist with chores, etc.
   Monitor bowel function. (Constipation is Advise patient:
    an early sign of toxicity. Administering      To report new episode of constipation
    water, laxative, stool softener before dose       immediately
    of vincristine may help decrease              Measures to decrease or eliminate
    constipation If fecal impaction occurs,           constipation, including increasing fluids,
    patient may need enemas.)                         fiber, etc. and to exercise if condition
                                                  To report constipation or abdominal pain
                                                      before taking laxative
   Monitor for signs of alopecia.               Advise patient:
    (Chemotherapeutic agents attack fastest       That alopecia is temporary, and that hair
    growing cells in body, including hair             will grow back once treatment is
    cells.)                                           completed; hair may be different texture
                                                      or color
                                                  About local support groups such as ACS
                                                  To get a wig and start wearing before hair
                                                      loss is severe
   Monitor GI problems. (Antineoplastics        Teach patient and caregivers:
    attack fastest growing cells in body,         Measures to obtain adequate nutrition,
    which includes cells in GI tract.)                such as supplements, frequent small
                                                      meals, high-calorie liquids, etc.
                                                  To take anti-emetic as soon as nausea
                                                      occurs, not to wait until severe vomiting
   Monitor IV site for extravasation. (Can      Instruct patient to immediately report any pain,
    cause tissue necrosis secondary to severe         discomfort, redness, swelling at IV site
    irritation if medication gets into tissues.)      during administration or after
                                                      administration is complete.
   Monitor for herpes zoster or chickenpox. Advise patient to:
     (If patient exposed, could experience           Avoid vaccinations while receiving
     severe case of the disease secondary to          vincristine
     fact that patient’s decreased immune          Avoid persons with chickenpox
     status does not allow ability to fight off    Inform household members that they
     any viral invasion.)                             should not receive live virus vaccinations
                                                      while patient receiving vincristine
                                Evaluation of Outcome Criteria
Evaluate the effectiveness of drug therapy by confirming that patient goals and expected
outcomes have been met (see “Planning”).
             Nursing Process Focus: Patients Receiving TAMOXIFEN (Nolvadex)
Assessment                                         Potential Nursing Diagnoses
Prior to administration:                                Anxiety, related to uncertain future,
 Obtain complete health history including                 body image changes secondary to
    allergies, drug history and possible drug              tamoxifen
    interactions                                        Knowledge, deficient, related to no
 Assess for presence or history of breast                 previous contact with tamoxifen or any
    cancer                                                 other drug taken as prophylaxis
                                                        Nutrition, inbalanced, less than body
                                                           requirements, related to nausea and
                                                           vomiting secondary to tamoxifen
                                                        Pain, acute, related to tumor flare
                                                        Sexual dysfunction, male, related to side
                                                           effects of tamoxifen
                Planning: Patient Goals and Expected Outcomes
Patient will:
     Demonstrate improved quality of life while on tamoxifen therapy,
     Complete recommended course of therapy
     Demonstrate knowledge of drug therapy and adverse reactions
     Maintain adequate nutrition
     Demonstrate maintenance of positive body image
       Interventions and (Rationales)              Patient Teaching/Discharge Planning
  Advise patient to be tested for estrogen-          Advise patient of importance of having
     positive receptors. (Tamoxifen is more              estrogen receptors tested.
     effective in tumors with high
     concentrations of positive estrogen
  Monitor for tumor flare. (Increased bone        Advise patient and caregiver:
     pain or increased tumor size may occur at        That increased bone pain or increased
     beginning of therapy, secondary to high             tumor size may occur at beginning of
     doses of tamoxifen being present in those           therapy that these symptoms will stop on
     areas.)                                             their own
                                                      To report symptoms so analgesia can be
  Monitor for vision changes. (Decreased          Instruct patient to:
     vision may be an irreversible adverse            Have eye exam before beginning
     reaction to tamoxifen.)                             tamoxifen therapy and periodically during
                                                      Report immediately any decreased vision
  Monitor for vaginal bleeding in post-              Instruct patient that vaginal bleeding is
     menopausal woman. (Although tamoxifen               not normal and she must report it
     is an anti-estrogen, it acts similar to             immediately.
     estrogen in body, simulating
    Monitor for other GU problems including      Advise patient:
     menstrual irregularities, impotence,            That there is an increased risk of
     erectile dysfunction.                              endometrial cancer with tamoxifen
                                                        therapy so she can make informed
                                                     To report any changes in normal
                                                        menstrual cycle
                                                     To report impotence
  Monitor for other side effects/adverse         Advise patient:
    reactions.                                       That side effects may occur, and to report
                                                        them: hot flashes, weight gain, pruritis,
                                                        vaginal discharge
                                                     They will stop when tamoxifen no longer
                                                        being taken
                                                     That some problems may not be due to
                                                        tamoxifen (such as chest pain), so it is
                                                        important to note them and report
  Monitor lab values. (CBC must be done          Instruct patient:
    weekly. If WBC <3500-4000, dose of               That appointments for lab studies must be
    tamoxifen must be held. Be aware that               kept
    incorrect increased serum calcium levels,        If showing signs of myelosuppression
    or increased T4 results in absence of               (fever, unusual fatigue, sore throat, etc.),
    hyperthyroidism may be reported.)                   avoid infections, etc. by staying away
                                                        from people with URIs, staying out of
                                                        wind or extremes of temperature, getting
                                                        adequate rest
  Monitor for photophobia. (Tamoxifen               Advise patient to wear sun screen,
    causes increased sensitivity to sunlight.)          sunglasses, long sleeves when out in sun.
  Monitor for commitment to tamoxifen               Advise patient that he/she must be
    therapy. (At current time, tamoxifen is             committed to taking tamoxifen for long
    recommended to be taken for 5 years.)               period of time, and to other restrictions
                                                        associated with it: preventing pregnancy,
                                                        routine lab studies, medical follow-ups,
                                Evaluation of Outcome Criteria
Evaluate the effectiveness of drug therapy by confirming that patient goals and expected
outcomes have been met (see “Planning”).

Shared By: